Phase II randomized, double-blind, placebo-controlled study of CPP-1X in patients with precancerous gastric lesions who are at high risk for gastric cancer.
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2017
Price : $35 *
At a glance
- Drugs Eflornithine (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 31 Jul 2017 New trial record
- 17 Jul 2017 According to a Cancer Prevention Pharmaceuticals media release, Vanderbilt University Medical Center is a center for this trial.
- 17 Jul 2017 According to a Cancer Prevention Pharmaceuticals media release, this trial is funded by the National Cancer Institute (NCI).